Hyderabad-based MSN Labs to begin phase III trial of Molnupiravir
The clinical trials will be performed on more than 2,400 subjects suffering from mild to moderate Covid-19, across over 40 sites in India
Hyderabad: Hyderabad-based pharmaceuticals company MSN Laboratories will initiate a phase III clinical trial of molnupiravir capsules for the treatment of Covid-19 in India.
MSN has received its clinical trial approval on May 19 from Drug Controller General of India (DCGI) to perform molnupiravir efficacy and safety study on mild to moderate Covid-19 patients.
The company will start its clinical trials in more than 40 sites across India and the first dosing is expected to begin soon. The clinical trials will be performed on more than 2,400 subjects suffering from mild to moderate Covid-19.
Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for Covid treatment. MSN’s R&D team has developed both the bulk drug (active pharmaceutical ingredient) and formulation.
As part of the Covid treatment range, MSN has already launched Favilow (favipiravir) in the strengths of 200mg, 400mg and 800mg, Oselow (oseltamivir) as 75 mg capsules and licensed Baridoz (baricitinib) recently with Eli Lilly.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
